in vivo ≠ in vitro [Power / Sample Size]

posted by dshah  – India/United Kingdom, 2022-07-25 13:19 (132 d 01:58 ago) – Posting: # 23171
Views: 642

Hi Mithu!

❝ Here the case is, we are dealing with some technology transfer products in which we could not change our test formulation which was meet the BE marginally at the time of initially filing. now due to this bottle neck, our thinking is if we take little large sample size, than we can manage variability (my expectation may be not correct).


As per regulatory acceptance- it is either acceptable or unacceptable. So is not best to describe it as marginally acceptable.

The in vitro assessment with recent batches of reference is important and also performing a comparative dissolution with older lot (if still available) can be useful.

Taking only larger size without consideration of in vitro assessment will not solve your problem.

Regards,
Divyen Shah

Complete thread:

UA Flag
Activity
 Admin contact
22,428 posts in 4,694 threads, 1,598 registered users;
11 visitors (0 registered, 11 guests [including 9 identified bots]).
Forum time: 14:18 CET (Europe/Vienna)

Operational hectic replaces
intellectual calms.    Alexander Huiskes

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5